The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Cost-effectiveness analysis of CAR-T therapy
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, describes how cost-effectiveness analyses for novel therapies are performed, focusing on CAR-T therapy. Dr Cliff comments on the approval and reimbursement procedure in the US and in other parts of the world. Dr Cliff also comments on how the benefit and cost-effectiveness of CAR-T therapy might differ for pediatric and adult patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
